<DOC>
	<DOCNO>NCT00003141</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy plus peripheral stem cell transplantation treat infant malignant brain spinal cord tumor .</brief_summary>
	<brief_title>Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Infants With Malignant Brain Spinal Cord Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose thiotepa infant malignant brain spinal cord tumor receive intensive chemotherapy . - Determine feasibility toxicity intensive chemotherapy peripheral blood stem cell ( PBSC ) rescue patient . - Assess feasibility harvest PBSCs patient . - Determine complete response rate overall event-free survival rate patient treat regimen . OUTLINE : This pilot , multicenter study . Patients undergo surgery diagnosis maximal tumor resection . Within 6 week surgery stable , patient begin induction chemotherapy comprise cisplatin IV 6 hour day 0 ; vincristine IV day 0 , 7 , 14 ; cyclophosphamide IV 1 hour day 1-2 ; etoposide IV 1 hour day 0-2 . Twenty four hour last cyclophosphamide dose , patient receive filgrastim ( G-CSF ) subcutaneously ( SC ) undergo peripheral blood stem cell harvest 2 day later . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Within 6 week induction chemotherapy , patient receive consolidation chemotherapy comprise carboplatin IV 2 hour day 0-1 follow immediately escalate dos thiotepa IV 2 hour . Patients undergo peripheral blood stem cell transplantation 48 hour last thiotepa dose . Patients receive G-CSF SC daily day 3 21 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Patients experience dose-limiting toxicity due thiotepa remove study . Patients follow 4 week , every 3 month 1 year , every 6 month 3 year , annually 3 year relapse . PROJECTED ACCRUAL : A total 83 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove malignant brain spinal cord tumor , include follow : Primitive neuroectodermal tumor Ganglioneuroblastoma Medulloblastoma neuroblastoma Desmoplastic medulloblastoma Medulloepithelioma Ependymoma neuroepithelioma Anaplastic ependymoma germ cell tumor Astrocytoma germinoma Anaplastic astrocytoma Embryonal carcinoma Glioblastoma endodermal sinus tumor Gliosarcoma malignant teratoma Choroid plexus carcinoma Mixed germ cell tumor Cerebellar sarcoma Pineoblastoma Atypical teratoid/rhabdoid tumor Choriocarcinoma Teratoma ( malignant malignant transformation ) Diffusely involved brain stem tumor allow evidence brain stem glioma CT scan MRI PATIENT CHARACTERISTICS : Age : 6 month le 3 year Performance Status : Not specify Life Expectancy : More 8 week Hematopoietic : Absolute neutrophil count great 1,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL Renal : Glomerular filtration rate creatinine clearance great 70 mL/min PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : Prior corticosteroid allow Radiotherapy : No prior radiotherapy Surgery : No 6 week since prior surgery Recovered prior surgery ( stable )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>embryonal childhood rhabdomyosarcoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>childhood spinal cord neoplasm</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>childhood central nervous system choriocarcinoma</keyword>
	<keyword>childhood central nervous system embryonal tumor</keyword>
	<keyword>childhood central nervous system germinoma</keyword>
	<keyword>childhood central nervous system mixed germ cell tumor</keyword>
	<keyword>childhood central nervous system teratoma</keyword>
	<keyword>childhood central nervous system yolk sac tumor</keyword>
</DOC>